home / stock / pirs / pirs news

PIRS News and Press, Pieris Pharmaceuticals Inc. From 11/11/19

Stock Information
Company Name: Pieris Pharmaceuticals Inc.
Stock Symbol: PIRS
Market: NASDAQ
Website: pieris.com
Menu
PIRS PIRS Quote PIRS Short PIRS News PIRS Articles PIRS Message Board
Get PIRS Alerts

News, Short Squeeze, Breakout and More Instantly...
PIRS - Pieris Pharma +4% premarket on Q3 beat

Pieris Pharmaceuticals ( PIRS ) Q3 results : Revenues: $15.1M (+81.9%). More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

PIRS - Pieris Pharmaceuticals EPS beats by $0.18, beats on revenue

Pieris Pharmaceuticals (NASDAQ: PIRS ): Q3 GAAP EPS of -$0.05 beats by $0.18 . More news on: Pieris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PIRS - Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM EST BOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin &#...

PIRS - Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announ...
PIRS - Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today an...

PIRS - Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announce...

PIRS - Forensic Stock Analysis: The Highest Positive And Negative Scoring Stocks For October

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
PIRS - ENDP, INMD, LTM and NXTC among midday movers

Gainers:  LATAM Airlines Group (NYSE: LTM ) +30% . Just Energy Group (NYSE: JE ) +26% . Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ) +20% . Tiziana Life Sciences PLC (NASDAQ: TLSA ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +14% . Ra Medical Systems, Inc. (NYSE: R...

PIRS - Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-R? Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress

BOSTON, MA / ACCESSWIRE / September 26, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, tod...

PIRS - RAD, BYND among premarket gainers

Marinus Pharmaceuticals (NASDAQ: MRNS ) +39%  on positive ganaloxone data . More news on: Marinus Pharmaceuticals, Inc., Pieris Pharmaceuticals, Inc., SAExploration Holdings, Inc., Stocks on the move, Read more ...

Previous 10 Next 10